Overview
Familial isolated hypoparathyroidism due to agenesis of the parathyroid glands is an extremely rare genetic condition in which the parathyroid glands fail to develop (agenesis), resulting in deficient or absent production of parathyroid hormone (PTH). PTH is essential for maintaining calcium and phosphorus balance in the body. Without adequate PTH, affected individuals develop hypocalcemia (low blood calcium) and hyperphosphatemia (high blood phosphorus), which can lead to a range of symptoms including muscle cramps, tingling and numbness in the hands, feet, and around the mouth (paresthesias), tetany (involuntary muscle contractions), and seizures. In severe neonatal cases, life-threatening hypocalcemic episodes may occur shortly after birth. The condition primarily affects the endocrine and musculoskeletal systems, and chronic hypocalcemia can also impact the nervous system, heart, kidneys, and eyes (e.g., cataracts with prolonged disease). This form of hypoparathyroidism is distinguished from other causes by its familial occurrence and the congenital absence of parathyroid gland tissue, without other associated developmental anomalies (such as those seen in DiGeorge syndrome). Mutations in genes critical for parathyroid gland development, including GCM2 (GCMB), have been identified in some families. The inheritance pattern can vary depending on the specific genetic defect involved. Treatment focuses on lifelong calcium and active vitamin D (calcitriol) supplementation to maintain normal serum calcium levels and prevent complications. Regular monitoring of blood calcium, phosphorus, and renal function is essential. Recombinant PTH therapy may be considered in refractory cases. Early diagnosis and consistent management can significantly improve quality of life and reduce the risk of serious complications such as seizures, cardiac arrhythmias, and renal calcifications.
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Familial isolated hypoparathyroidism due to agenesis of parathyroid gland.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Familial isolated hypoparathyroidism due to agenesis of parathyroid gland at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Familial isolated hypoparathyroidism due to agenesis of parathyroid gland.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Familial isolated hypoparathyroidism due to agenesis of parathyroid gland.
Community
No community posts yet. Be the first to share your experience with Familial isolated hypoparathyroidism due to agenesis of parathyroid gland.
Start the conversation →Latest news about Familial isolated hypoparathyroidism due to agenesis of parathyroid gland
No recent news articles for Familial isolated hypoparathyroidism due to agenesis of parathyroid gland.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Familial isolated hypoparathyroidism due to agenesis of parathyroid gland
What is Familial isolated hypoparathyroidism due to agenesis of parathyroid gland?
Familial isolated hypoparathyroidism due to agenesis of the parathyroid glands is an extremely rare genetic condition in which the parathyroid glands fail to develop (agenesis), resulting in deficient or absent production of parathyroid hormone (PTH). PTH is essential for maintaining calcium and phosphorus balance in the body. Without adequate PTH, affected individuals develop hypocalcemia (low blood calcium) and hyperphosphatemia (high blood phosphorus), which can lead to a range of symptoms including muscle cramps, tingling and numbness in the hands, feet, and around the mouth (paresthesias)
At what age does Familial isolated hypoparathyroidism due to agenesis of parathyroid gland typically begin?
Typical onset of Familial isolated hypoparathyroidism due to agenesis of parathyroid gland is neonatal. Age of onset can vary across affected individuals.